-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pre-approved trials have shown that a messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has good safety, but these trials are limited by scale and patient mix
.
The safety of the BNT162b2mRNA vaccine in terms of a wider range of potential adverse events needs to be evaluated
Recently, a research article was published in the top medical journal NEJM.
Researchers used data from Israel's largest healthcare organization to evaluate the safety of the BNT162b2mRNA vaccine
Diagnose infection
In the vaccination analysis, the vaccinated group and the control group each contained 884,828 subjects
.
Vaccination and myocarditis (hazard ratio of 3.
Arrhythmia thrombosis In this nationwide mass vaccination study, the BNT162b2 vaccine was not associated with the increased risk of most adverse events assessed